Emergingby GlyphCambrian Bio
Joined in Longevity biotech. Clinical-stage company developing drugs that target metabolic pathways that decline with age, such as AMPK and mTOR.
Cambrian Bio
StartupUS1 field
Where it works
| Technology | ||
|---|---|---|
| Longevity biotechClinical-stage company developing drugs that target metabolic pathways that decline with age, such as AMPK and mTOR. | Clinical-stage company developing drugs that target metabolic pathways that decline with age, such as AMPK and mTOR. | cambrianbio.com |
About
- Source
- cambrianbio.com (official, added by seed)
- First seen
- Sep 25, 2026
- Last seen
- Oct 6, 2026
- Across Glyph
- Cambrian Bio on Companies
Cambrian Bio
Added in Longevity biotech. Clinical-stage company developing drugs that target metabolic pathways that decline with age, such as AMPK and mTOR.